drugset / Trial / NCT05095168
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
This is a single site, single dose escalation study in healthy subject with CAN106. The study is to assess the safety and tolerability of single escalating doses of CAN106; to characterize the PK and PD profile of CAN106; and to evaluate the immunogenicity of CAN106 injection.
Timeline
- Start
- 2021-02-22
- Primary completion
- 2021-11-30
- Completion
- 2021-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OMOPRUBART | Monoclonal antibody | — | Intravenous |